Agenus’ Phase 1 clinical trial results have been published in Nature
Agenus shared their publication on investigational immunotherapeutic agents in Nature:
“Results from our Phase 1 clinical trial have been published in Nature Portfolio’s Nature Medicine.
This publication highlights the potential of our novel immunotherapy combination, botensilimab plus balstilimab, for treating microsatellite stable metastatic colorectal cancer (MSS mCRC), a cancer type historically resistant to immunotherapy.”
Authors: Andrea J. Bullock, Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Joseph E. Grossman, Michael S. Gordon, Breelyn A. Wilky, Agustin Pimentel, Daruka Mahadevan, Ani S. Balmanoukian, Rachel E. Sanborn, Gary K. Schwartz, Ghassan K. Abou-Alfa, Neil H. Segal, Bruno Bockorny, Justin C. Moser, Sunil Sharma, Jaymin M. Patel, Wei Wu, Dhan Chand, Katherine Rosenthal, Gabriel Mednick, Chloe Delepine, Tyler J. Curiel, Justin Stebbing, Heinz-Josef Lenz, Steven J. O’Day & Anthony B. El-Khoueiry
Read the full article.
Source: Agenus/LinkedIn
Other posts from Agenus on OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023